The U.S. definitely does not have a lock on the marijuana industry.
Over the past two years, private companies from the United States have put roughly $50 million into the Israeli medical marijuana trade alone.
Those tens of millions, according to Reuters, have gone towards “licensing Israeli medical marijuana patents, cannabis agro-tech startups and firms developing delivery devices such as inhalers.”
One of the reasons Israel’s information is so valuable is simply because the U.S. federal government is still standing in the way of scientific research into the medicinal benefits of cannabis, how it should and shouldn’t be used, etc.
And Israel, in turn, has created a nearly perfect hub of research with very little actual demand for MMJ – only 23,000 patients have signed up for access from nine licensed suppliers in the entire country. The U.S. market is gigantic by comparison.
